For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Maintaining weight loss after GLP-1 treatment is challenging — get expert tips on how to keep those pounds off for good.

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...